Immix Biopharma(US:IMMX) Globenewswireยท2025-05-23 13:05Company Overview - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases [7] - The lead candidate is NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy, currently being evaluated in the NEXICART-2 study [4][7] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [4][7] Clinical Trial Updates - The NEXICART-2 clinical trial is actively enrolling patients, with 14 U.S. sites currently participating, an increase of 10 sites since the last update [1][2] - The company anticipates completing the NEXICART-2 clinical trial ahead of schedule due to robust enrollment and demand [2] - The trial aims to enroll 40 patients with preserved heart function who have not previously received BCMA-targeted therapy, focusing on safety and efficacy as primary endpoints [3] Market Insights - The U.S. prevalence of relapsed/refractory AL Amyloidosis is estimated to grow at 12% annually, reaching approximately 33,277 patients by 2024 [6] - The AL Amyloidosis market was valued at $3.6 billion in 2017 and is projected to reach $6 billion by 2025 [6] Upcoming Presentations - Phase 1/2 interim readout data from the NEXICART-2 trial will be presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago from May 30 to June 3, 2025 [2]